目的:观察多西他赛联合氟尿嘧啶治疗进展期胃癌的疗效及安全性。方法:84例进展期胃癌患者随机分为A、B两组42例。A组采用多西他赛联合氟尿嘧啶化疗,B组采用多西他赛联合替吉奥化疗。两组患者均以21 d为1个周期,至少化疗2个周期。观察两组患者治疗后近期临床疗效、患者体能状态改善情况以及药品不良反应发生情况。结果:两组患者总有效率比较差异无统计学意义(P>0.05),但A组体能状态改善率(40.48%)显著高于B组(20.24%),差异有统计学意义(P<0.05)。A组血小板下降和中性粒细胞下降发生率显著低于B组(P<0.05)。结论:多西他赛联合氟尿嘧啶治疗进展期胃癌临床疗效显著,能显著改善患者体能状态,且不良反应相对较少。 Objective: To observe the efficacy and safety of docetaxel plus fluorouracil in the treatment of advanced gastric cancer. Methods: Eighty-four patients with advanced gastric cancer were randomly divided into two groups (A and B), 42 cases. Docetaxel combined with fluorouracil chemotherapy was used in group A, and docetaxel combined with dipyridamole in group B. Two groups of patients were 21 d for a cycle, at least 2 cycles of chemotherapy. To observe the short-term clinical curative effect of two groups of patients after treatment, the improvement of physical fitness status of patients and the occurrence of adverse drug reactions. Results: There was no significant difference in the total effective rate between the two groups (P> 0.05). However, the improvement rate of physical status in group A (40.48%) was significantly higher than that in group B (20.24%), with significant difference ). The incidence of thrombocytopenia and neutropenia in group A was significantly lower than that in group B (P <0.05). Conclusion: Docetaxel and fluorouracil are effective in treating advanced gastric cancer, which can significantly improve the physical status of patients with less adverse reactions.